- Trials with a EudraCT protocol (62)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
62 result(s) found for: Mycobacterium Tuberculosis.
Displaying page 1 of 4.
EudraCT Number: 2010-023491-25 | Sponsor Protocol Number: MFX468 | Start Date*: 2011-01-18 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: Pharmacokinetics and safety of moxifloxacin; a dose escalation in patients with tuberculosis | |||||||||||||
Medical condition: Tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017430-49 | Sponsor Protocol Number: QFT-ECC-01 | Start Date*: 2010-04-16 | |||||||||||
Sponsor Name:Dr Miguel Santín Cerezales | |||||||||||||
Full Title: Ensayo clínico de dos estrategias para la toma de decisiones terapéuticas en el estudo de contactos de tuberculosis: estrategia estándar, basada en la prueba de la tuberculina (PT) sola frente a la... | |||||||||||||
Medical condition: Infección Tuberculosa latente | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006765-82 | Sponsor Protocol Number: MOXEP | Start Date*: 2009-05-29 | |||||||||||||||||||||
Sponsor Name:ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI | |||||||||||||||||||||||
Full Title: Preventive therapy for multidrug-resistant tuberculosis: a multicentre clincal trial. | |||||||||||||||||||||||
Medical condition: Close contacts of an infectious respiratory of a MDR-TB who are diagnosed with tuberculosis infection that is likely to have been acquired from the MDR-TB case will be eligible for inclusion in th... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000653-23 | Sponsor Protocol Number: TMC207-TiDP13-C210 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
Full Title: A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Myc... | |||||||||||||
Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Prematurely Ended) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008444-25 | Sponsor Protocol Number: TMC207-TiDP13-C209 | Start Date*: 2009-06-04 | |||||||||||
Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
Full Title: A Phase II, open-label trial with TMC207 as part of a multi-drug resistant tuberculosis (MDR-TB) treatment regimen in subjects with sputum smear-positive pulmonary infection with MDR-TB. | |||||||||||||
Medical condition: Sputum smear-positive pulmonary multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002202-30 | Sponsor Protocol Number: R207910BAC2001 | Start Date*: 2004-10-18 |
Sponsor Name:Tibotec Pharmaceuticals Ltd. | ||
Full Title: An open label study to evaluate the effects on Mycobacterium tuberculosis, safety, tolerability and pharmacokinetics of single doses of R207910, in treatment naive patients with mycobacterium tuber... | ||
Medical condition: Tuberculosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003372-23 | Sponsor Protocol Number: TMC207-C211 | Start Date*: 2015-05-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antimycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of... | |||||||||||||
Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021125-12 | Sponsor Protocol Number: TMC207TBC3001 | Start Date*: 2011-09-16 | |||||||||||
Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
Full Title: Early access of TMC207 in combination with other anti-tuberculosis (TB) drugs in subjects with extensively drug resistant (XDR) or pre-XDR pulmonary TB | |||||||||||||
Medical condition: Tuberculosis (TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004462-40 | Sponsor Protocol Number: TMC207-TiDP13-C208 | Start Date*: 2007-12-20 | |||||||||||
Sponsor Name:Tibotec BVBA | |||||||||||||
Full Title: A Phase II, placebo-controlled, double-blind, randomized trial to evaluate the anti-bacterial activity, safety, and tolerability of TMC207 in subjects with sputum smear-positive pulmonary infection... | |||||||||||||
Medical condition: Tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005617-36 | Sponsor Protocol Number: TESEC-06 | Start Date*: 2012-05-30 | |||||||||||
Sponsor Name:Statens Serum Institut | |||||||||||||
Full Title: A phase III contact tracing trial comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomized split body safety assessment of C-Tb ve... | |||||||||||||
Medical condition: Tuberculosis diagnostic tool | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000513-39 | Sponsor Protocol Number: LIN-interaction-01 | Start Date*: 2011-07-27 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: The pharmacokinetic effect of clarithromycin on the AUC0-12h of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients | |||||||||||||
Medical condition: Multidrug-resistant and extensively drug-resistant tubeculosis (MDR/XDR-TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005492-13 | Sponsor Protocol Number: TMC207TBC1002 | Start Date*: 2013-03-26 | |||||||||||
Sponsor Name:Janssen infectious diseases BVBA | |||||||||||||
Full Title: A Phase I, open-label, randomized, 3-way crossover study in 3 Panels of healthy, adult subjects to assess the relative bioavailability of TMC207 following single-dose administration of two pediatri... | |||||||||||||
Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003301-22 | Sponsor Protocol Number: AC-R6 | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:Archivel Farma S.L. | |||||||||||||
Full Title: A phase IIB study to explore the efficacy and safety of the concomitant administration of RUTI® immunotherapy with the standard treatment in patients with TB (CONSTAN) | |||||||||||||
Medical condition: Pulmonary Tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017296-17 | Sponsor Protocol Number: TESEC-03 | Start Date*: 2011-04-04 | |||||||||||
Sponsor Name:Statens Serum Institut | |||||||||||||
Full Title: A phase IIa specificity trial of the diagnostic agent C-Tb, when given intradermally by the Mantoux technique to healthy volunteers previously vaccinated with BCG | |||||||||||||
Medical condition: The intended indication for the product is to be a diagnostic tool to detect infection with M.tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022302-41 | Sponsor Protocol Number: FLISH-ILT | Start Date*: 2011-03-03 | ||||||||||||||||
Sponsor Name:Consorcio de Apoyo a la Investigación Biomédica en Red (CAIBER) | ||||||||||||||||||
Full Title: Ensayo clínico prospectivo, aleatorizado, comparativo de la eficacia y seguridad del levofloxacino versus isoniazida en el tratamiento de la infección latente tuberculosa del trasplante hepático | ||||||||||||||||||
Medical condition: Pacientes en lista de espera de trasplante hepático | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002514-40 | Sponsor Protocol Number: CISTA-TB | Start Date*: 2019-10-31 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with pulmonary tuberculosis: a new therapy for tuberculosis d... | |||||||||||||
Medical condition: Pulmonary Mycobacterium tuberculosis infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001184-24 | Sponsor Protocol Number: SXT8469 | Start Date*: 2013-08-20 |
Sponsor Name:UMCG | ||
Full Title: Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients with Tuberculosis | ||
Medical condition: Tuberculosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000224-41 | Sponsor Protocol Number: IDANAT2 | Start Date*: 2008-08-26 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransfe... | |||||||||||||
Medical condition: pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022271-59 | Sponsor Protocol Number: 242-09-213 | Start Date*: 2011-07-19 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dos... | |||||||||||||
Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005664-88 | Sponsor Protocol Number: HB996 | Start Date*: 2006-12-08 |
Sponsor Name:University of Oxford | ||
Full Title: Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A ... | ||
Medical condition: Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.